mediumClinical trial2025-07-01
Oral NLRP3 inhibitor dapansutrile enters clinical trials for CAPS
Cryopyrin-Associated Periodic Syndromes →Summary
Dapansutrile (OLT1177), an oral NLRP3 inhibitor with favorable safety profile, is in Phase 2a clinical trial for CAPS maintenance therapy (NCT04524858), potentially replacing injectable biologics.
ID: cryopyrin-associated-periodic-syndromes-update-3Type: clinical_trialImpact: medium